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Abstract Conversion of latent proteases to the active form
occurs by various mechanisms characteristic for different
protease families. Here we report that the disintegrin metallo-
protease ADAM 12-S is activated by Cu(II). Copper activation
is distinct from the cysteine switch component of latency:
elimination of the ADAM 12 cysteine switch by a point mutation
in the propeptide had no effect on copper activation, whereas
mutation of an unpaired cysteine residue in the catalytic domain
resulted in a mutant form of ADAM 12-S that was insensitive to
copper. This suggests a multi-step activation mechanism for
ADAM 12 involving both furin cleavage and copper
binding. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
ADAMs (A disintegrin and metalloprotease) are a family of
cell surface or secreted proteins that are related to snake ven-
om metalloproteases and matrix metalloproteases (MMPs).
ADAMs function in a wide variety of physiological processes,
by virtue of either their cell adhesive activity or their proteo-
lytic activity [1^4]. ADAM 12 has been implicated in myo-
genesis and tumorigenesis [5^7]. Human ADAM 12 is ex-
pressed in two forms, a membrane-anchored form (ADAM
12-L) typical for the ADAM family, and a shorter form
(ADAM 12-S) that is secreted as a soluble protein [6].
ADAM 12-S appears to be one of the proteases responsible
for cleavage of IGFBP-3 in blood during pregnancy [8,9].
Protease function in vivo can be regulated at several levels.
A common means of modulating function is by delaying acti-
vation of the protease until it reaches its target site. Both
ADAM proteases and MMPs are synthesized as zymogens,
in which the N-terminal prodomain represses proteolytic ac-
tivity by means of a cysteine switch. This latency mechanism
involves an unpaired cysteine residue in the prodomain that
directly coordinates the zinc ion at the catalytic site [10,11].
Activation of most ADAM proteases is initiated in the
trans-Golgi network, when furin cleaves the propeptide from
the protease [4,12]. Activation of proMMPs occurs in the
extracellular environment in a stepwise manner, where the
¢rst step is cleavage of the propeptide by an exogenous pro-
tease at a speci¢c site, followed by complete removal of the
propeptide either by autocleavage or by intermolecular pro-
teolysis [13]. In vitro, proMMP activation can be initiated by
oxidizing or thiol-modifying reagents, and it is possible that
this mechanism also functions in vivo. Such reagents function
by modifying the unpaired cysteine residue in the propeptide,
thereby inactivating the cysteine switch [14]. However, in
some cases these oxidizing or thiol-modifying reagents acti-
vate proMMPs by an unknown mechanism that is cysteine
switch-independent [15,16].
In this study, using puri¢ed recombinant ADAM 12-S pro-
tease, we have found that Cu(II) can activate ADAM 12-S by
a cysteine switch-independent mechanism. Our results suggest
that activation of ADAM 12 and possibly other ADAM pro-
teases is a multistep process involving more than just furin
cleavage of the propeptide. These data may also provide new
insights into the complicated activation mechanism of MMPs.
2. Materials and methods
2.1. Reagents
All chemicals were purchased from Sigma. Chloride salts of diva-
lent transition metal ions were used. Puri¢ed human K2-macroglobu-
lin (K2M) was kindly provided by Claus Oxvig (University of Aarhus,
Denmark).
2.2. Preparation of ADAM 12-S protein
Recombinant human ADAM 12-S protein (GenBank accession
number AF023477) was puri¢ed as previously described [9]. The
C179S mutation as well as the furin site mutation allowing expression
of the ADAM 12-S proform have been published previously [12]. The
C273A mutation was made by site-directed mutagenesis on ADAM
12-S cDNA using the GeneEditor site-directed mutagenesis system
from Promega. Mutant ADAM 12 cDNAs were cloned in the
pCEP4 expression vector (Invitrogen), yielding plasmids p1573
(C179S), p1572 (furin site mutation), and p1630 (C273A). They
were transfected into 293-EBNA cells, and the mutant proteins were
puri¢ed as for wild-type ADAM 12-S [9].
2.3. Protease assays
Assays were carried out in 50 mM PIPES (pH 7.0), 50 mM NaCl,
2 mM CaCl2, 0.5 mg/ml CHAPS at 37‡C for 2 h. ADAM 12-S was
included at 0.1 WM, based on an extinction coe⁄cient at 280 nm of
67.8 mM31. K2M was included at a concentration of 0.5 mg/ml. Re-
actions were terminated by boiling in reducing SDS sample bu¡er and
analyzed by SDS^PAGE on 6% Tris-glycine gels (Novex), followed by
Western blotting using a polyclonal antibody against the ADAM 12
cysteine-rich domain [17]. Detection was performed with a horserad-
ish peroxidase-conjugated second antibody and the chemilumines-
cence SuperSignal West Pico reagent from Pierce.
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2.4. Gel ¢ltration chromatography
8 Wg puri¢ed ADAM 12-S protein was applied to a Superose 12 HR
column, using the Aî KTA Basic FPLC system (Amersham Pharmacia
Biotech) at a £ow rate of 0.5 ml/min. The column bu¡er was 20 mM
Tris (pH 7.5), 200 mM NaCl, 1 mg/ml CHAPS. Absorbance at 280
nm was used to monitor the eluant, and peak fractions were analyzed
by SDS^PAGE on a 10% Tris^glycine gel (Novex), followed by im-
munoblotting using antibodies against both the cysteine-rich domain
and the propeptide of ADAM 12.
3. Results and discussion
We examined the requirement of ADAM 12-S protease for
biologically relevant transition metal ions, making use of the
K2M cross-linking reaction. In previous studies we used con-
ditioned medium from transfected COS cells as a source of
ADAM 12-S, while in this study we used puri¢ed ADAM 12-
S [11,12]. There was no detectable protease activity in the
absence of transition metal ions (Fig. 1A). Both Zn(II) and
Cu(II) were strong activators of ADAM 12-S protease, while
the other metal ions had no e¡ect. In the presence of 50 WM
Zn(II) or 10 WM Cu(II), most of the ADAM 12-S was con-
verted to high molecular weight K2M complexes, showing that
the majority of the ADAM 12-S molecules were proteolyti-
cally active.
These reactions contain two proteins, hence it is possible
that Zn(II) or Cu(II) stimulated activity by binding to either
K2M or ADAM 12-S. Another assay for ADAM 12-S pro-
tease is the autocleavage of the ADAM 12-S proform that
occurs upon chemical or genetic inactivation of the cysteine
switch [11]. This assay has the advantage that the only protein
present is ADAM 12-S. Fig. 1B shows that the only transition
metal ion capable of activating the ADAM 12-S proform was
Cu(II). Autocleavage was detectable at 1 WM Cu(II) and was
complete at 10 WM Cu(II). Western blotting with domain-
speci¢c antibodies showed that cleavage occurred near the
junction of the prodomain and the catalytic domain (data
not shown). Higher concentrations of Cu(II) resulted in fur-
ther degradation of the protease.
Copper and other transition metal ions are capable of
oxidizing proteins at amino acid residues such as His or Cys
[18]. Such metal-catalyzed oxidation can be highly speci¢c. In
the presence of a reducing agent (e.g. ascorbate), Cu(II) can
bind to and oxidize a single amino acid residue in a protein,
resulting in dramatic changes in protein structure [19^21]. We
tested for activation of ADAM 12-S protease by metal-cata-
lyzed oxidation using the ascorbate/Cu(II)/O2 system [21,22].
ADAM 12-S proform was incubated with 0.2 WM Cu(II), at a
ratio of two copper ions per molecule of ADAM 12-S. At this
concentration of copper, there was no detectable autoproteol-
ysis (Fig. 2A). Addition of 100 WM ascorbate resulted in acti-
vation of ADAM 12-S protease. Ascorbate alone had no ef-
fect. When the enzymatic activity of the proform was
destroyed by heat treatment prior to incubation with copper
or copper/ascorbate, no cleavage was seen (Fig. 2B). Conver-
sion of 92 kDa ADAM 12-S to a 68 kDa form was therefore
not due to direct cleavage of peptide bonds by copper, but
rather autocatalysis of the activated proform.
We considered the possibility that copper activation of
ADAM 12 protease involves the cysteine switch. Cys179 in
the ADAM 12 prodomain is an unpaired cysteine residue
which represses proteolytic activity by coordinating the zinc
ion at the active site of the catalytic domain [11]. The ADAM
12 propeptide remains bound to the protease after cleavage by
furin [9], therefore the cysteine switch is potentially still func-
tional in furin-cleaved ADAM 12-S. Cu(II) could conceivably
disengage the cysteine switch by binding to or oxidizing
Fig. 1. A: K2M crosslinking assay on ADAM 12-S protease, carried
out either in the absence of transition metal ions (¢rst lane) or with
individual ions at the indicated concentration. Cleavage of the K2M
bait region results in conversion of 68 kDa ADAM 12 protease to
high molecular weight cross-linked products. B: Autocleavage of
ADAM 12-S proform. ADAM 12-S protein containing a mutation
to prevent cleavage of the propeptide by furin was puri¢ed and in-
cubated either in the absence of transition metal ions (¢rst lane) or
with individual ions at the indicated concentration.
Fig. 2. Autocleavage of ADAM 12-S proform induced by metal-cat-
alyzed oxidation. A: The proform was incubated with Cu(II) and
ascorbate at the indicated concentrations. Conversion of the 92 kDa
proform to a 68 kDa form was detected by immunoblotting.
B: The proform was incubated at 70‡C for 15 min to destroy its
catalytic activity, prior to incubation with Cu(II) and ascorbate.
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Cys179, similar to the way in which ADAM 12 or MMP
proforms can be activated by alkylation of the free cysteine
in the propeptide [11,13]. A mutant form of ADAM 12-S was
prepared in which Cys179 was changed to Ser. The C179S
mutant behaved identically to wild-type ADAM 12-S; it was
activated by both Cu(II) and Zn(II) (Fig. 3). We conclude that
the cysteine switch and copper activation are two separate
components of the ADAM 12 latency/activation mechanism.
The sequence of the ADAM 12 prodomain and catalytic
domain was examined for amino acid residues likely to con-
stitute a copper binding site; cysteine and histidine are good
candidates based on comparison to known copper binding
proteins [23,24]. There is a cysteine residue in the ADAM
12 catalytic domain that is predicted to be unpaired, based
on homology to other ADAM proteases [2]. We hypothesized
that this residue, Cys273, together with histidine residues in
the catalytic domain and/or propeptide, binds a copper ion,
leading to a change in conformation of ADAM 12-S, and
subsequent activation. ADAM 12-S protein with Cys273 mu-
tated to Ala was puri¢ed as tested in the K2M cross-linking
assay. This ADAM 12-S mutant was not activated by Cu(II)
(Fig. 3). This is a speci¢c e¡ect rather than simple misfolding
of the protease due to the mutation, because the C273A mu-
tant does have K2M cross-linking activity in the presence of
Zn(II).
These data, together with previously published results on
the ADAM 12 cysteine switch [11], suggest a multi-step acti-
vation mechanism for ADAM 12-S protease. Newly synthe-
sized ADAM 12-S in the endoplasmic reticulum is latent, due
to coordination of the zinc ion at the active site by Cys179 in
the prodomain. As it passes through the trans-Golgi network,
ADAM 12-S is cleaved at the junction between the prodomain
and the catalytic domain, but the propeptide remains bound
to the protease. Furin-cleaved ADAM 12-S is markedly more
active than the ADAM 12-S proform when assayed using
either K2M [11,12] or IGFBP-3 as a substrate (F. Loechel,
unpublished data), but an additional step involving binding
of Cu(II) appears to be required for full activity of ADAM
12-S protease. This second activation step does not involve
the cysteine switch (Fig. 3), nor does it seem to involve dis-
sociation of the propeptide from the protease. The propeptide
remains bound to the protease after furin cleavage, as evi-
denced by the fact that the two polypeptides migrate as a
complex in gel ¢ltration chromatography (Fig. 4A). A trace
of free propeptide is also detectable. The protease/propeptide
complex remained intact when chromatography was per-
formed in the presence of 10 WM CuCl2 (Fig. 4B). In contrast,
the propeptide could be dissociated from the protease by a
brief incubation at pH 2.5 (Fig. 4C).
We favor a model in which copper binding, rather than
dissociating the propeptide, results in oxidation of one of
the amino acid residues in the binding site, and thereby
changes the conformation of ADAM 12-S so that it is fully
active. In vivo, such a two-step activation mechanism would
allow for tighter control of ADAM 12 protease activity in
blood or in the extracellular space. Copper is sequestered by
proteins such as ceruloplasmin, and there is thought to be
little free copper available [25]. Transfer of a copper ion to
ADAM 12 protease in vivo could occur either directly from a
copper chaperone, similar to what has been demonstrated for
copper charging of superoxide dismutase [23], or by transient
Fig. 3. K2M crosslinking assay on ADAM 12-S protease, comparing
copper activation of wild-type ADAM 12-S to ADAM 12-S con-
taining a point mutation in the cysteine switch (C179S) or a point
mutation in an unpaired cysteine residue in the catalytic domain
(C273A). Reactions were carried out either with no transition metal
ions, with 10 WM CuCl2, or with 50 WM ZnCl2.
Fig. 4. Gel ¢ltration chromatography on wild-type ADAM 12-S
protein. A: Control. B: In the presence of 10 WM CuCl2. C:
Treated with pH 2.5 for 1 min prior to chromatography. Immuno-
blotting of the peak fractions using antibodies against both the pro-
peptide and the protease showed that peak 1 contained the propep-
tide/protease complex, and peak 2 contained free propeptide. 10 WM
CuCl2 had no e¡ect, while low pH dissociated the propeptide/pro-
tease complex.
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increases in free copper concentration as a result of oxidation
of proteolysis of copper-sequestering proteins.
Is copper likely to be involved in the activation of other
proteases? Among ADAM proteases, ADAM 13 and ADAM
19 are good candidates, because they contain an unpaired
cysteine residue in the catalytic domain at the same position
as Cys273 of ADAM 12 [26]. Copper activation of ADAM 12
protease may have a parallel in the MMP family of zinc
metalloproteases. It is known that MMPs, in addition to the
zinc ion at the catalytic site, have an additional binding site
for a ‘structural’ zinc in the catalytic domain [1]. Zinc occu-
pancy of this site in a given MMP is dependent on the pres-
ence of other domains, as well as on the method of puri¢ca-
tion [27,28]. It has been proposed that the second zinc ion is
part of an additional activation step, separate from the MMP
cysteine switch [29]. It would be interesting to test whether
this zinc binding site is actually a copper binding site that
plays a role in MMP activation in vivo.
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